The Argentine laboratory Richmond manufactured 21,000 doses of the Sputnik V vaccine and will begin in June the mass production

Argentina became one of the few countries where vaccines are produced against the coronavirus, but the process had been kept secret until today.The Richmond laboratory reported that it manufactured and sent a dose batch of SPTunik V to Moscow to obtain Russian approval and start mass production in one of its plants located in Buenos Aires.

The firm communicated to the capital stock exchange that the first lots "are being sent to the Gamaleya Center for evaluation, while other trials are carried out in parallel in our laboratories".

Allegados a la compañía especificaron a Infobae que el lote enviado a Rusia incluye 21.176 dosis que serán testeadas y sometidas a pruebas de calidad en el Instituto Gamaleya como paso previo a su fabricación en escala, que comenzaría en junio.

Marcelo Figueiras, presidente de Richmond, se encuentra en Rusia junto a su equipo de trabajo para supervisar las pruebas y cerrar los detalles del método de trabajo que podría ponerse en marcha en pocos días.He recently posted a photo on his Instagram account: "There is a team, passion, a lot.He had already been in the Russian capital at the beginning of the year to sign the agreement that allowed him to start making the first doses of the vaccine in Argentina.

The laboratory stressed: “Argentina is the first Latin American country that began the process of transfer of the Sputnik V vaccine, all of which was possible thanks to the collaboration of RDIF and its strategic partners. De no mediar dificultades, a la mayor brevedad posible, comenzaría una etapa de producción de Sputnik V en nuestro país”.

En tanto, Kirill Dmitriev, director ejecutivo del RDIF, indicó en un comunicado: “Hoy nos complace anunciar que Argentina se ha convertido en el primer país de la región en lanzar la producción. Sputnik V ha sido aprobada en más de 10 países de América Latina, la producción en Argentina va a facilitar las entregas a otros socios en la región”.

Este proceso es parte de un entendimiento que se firmó el 25 de febrero entre el Fondo Ruso de Investigación y el laboratorio argentino, que podría convertirse en un hito significativo en la lucha contra el avance del virus en la Argentina y la región.

At the same time, Richmond works on the formation of a trust of between 70 and 100 million dollars for the construction of a new plant that will have the possibility of manufacturing up to 500 million doses per year.

Russia, rather than signing sales agreements, has focused on expanding production capabilities, transferring it abroad.

This week signed an agreement with Chinese Laboratory Hualan Biological Bacterin to produce 100 million doses.

A fines de marzo, acordó con la empresa farmacéutica china Shenzhen Yuanxing Gene-tech para fabricar 60 millones de dosis.Previously, he had signed with other great producers from India. Se trata de Virchow Biotech (300 millones de dosis), Stelis (200 millones) y Hetero (100 millones).In the case of Virchow, RDIF indicated that the technology transfer would be completed in the second quarter of 2021, and will be followed by large -scale commercial production.And there is another agreement signed in Serbia.

“Las alianzas en materia de vacunas son la única manera de superar la pandemia. El mundo continúa su lucha contra el coronavirus, y vemos un interés creciente en la Sputnik V”, dijo entonces Dmitriev.

La vacuna se basa en una plataforma probada y bien estudiada de vectores adenovirales humanos y utiliza dos vectores diferentes para las dos inyecciones, lo que proporciona inmunidad con una duración más prolongada que las vacunas que utilizan el mismo mecanismo de administración para ambas inyecciones.

The effectiveness of the Russian vaccine, according to scientific studies published in Lancet, is 91.6%, one of the highest rates recorded to date.In addition, this week a new study carried out on the almost 4 million Russians who have been vaccinated with this formula showed an efficacy of 97.6%.

How to Join A Zoom Meeting On PC or Mac (How To of The Day) https: // t.co/bwyapz5dgu https: // t.CO/TKUXU2XUPD

— Mobile Tech Sun Nov 01 18:29:37 +0000 2020

Sus buenos resultados, así como su facilidad para el almacenamiento (sin necesidad de congelación) y la falta de efectos adversos registrados hasta la fecha han atraído el interés de decenas de países, incluso de la Unión Europea, luego de meses de suspicacia por temores de injerencia política en el proceso de aprobación.In addition, it has a low price, less than $ 10 per injection.

The Sputnik statement:

Moscow, April 20, 2021 - The Russian Direct Investment Fund (RDIF, the Sovereign Investment Fund of the Russian Federation) and the Pharmaceutical Company Laboratories Richmond Sacif announce the production of the first lot of the Russian vaccine against the coronavirus, Sputnik V , in Argentina.

Argentina has become the first country in Latin America to start the production of the Sputnik V vaccine.RDIF and its partners have made a technology transfer to Richmond laboratories;The first batch produced will be delivered to the Gamaleya center to perform the corresponding quality control.It is expected that the large -scale production of Sputnik V in Argentina begins in June.

Argentina was the first Latin American country to officially register Sputnik V in its territory.The registration was carried out through an emergency use authorization (Emergency Use Authorization), and vaccination began in Argentina on December 29, 2020.

The vaccine produced in Argentina can then be exported to other countries in Central America and Latin America.

Currently, Sputnik V is registered in 60 countries, with a total population of 3 billion people.The effectiveness of the vaccine is 97.6%, according to the result of the analysis of data on the incidence of the coronavirus among the Russians vaccinated with both components in the period between December 5, 2020 and March 31, 2021.

The vaccine is based on a proven and well -studied platform of human adenoviral vectors and uses two different vectors for two administrations during vaccination, which provides a more durable immunity than vaccines that use the same administration mechanism for both inoculation.

Kirill Dmitriev, Executive Director (CEO) of the Direct Investment Fund of Russia (RDIF), has declared:

“Argentina was the first in Latin America to approve the use of the Sputnik V vaccine and start vaccinating the population.Today we are pleased to announce that Argentina has also become the first state of the region to start the production of Sputnik V thanks to the RDIF and Laboratories association Richmond.Sputnik V is approved in more than 10 countries in Latin America and Central America, and production in Argentina will allow deliveries to our other partners ”.

Marcelo Figueiras, president of Richmond laboratories, has declared:

“Richmond Laboratories is proud of RDIF's support, which trusted our scientific and technological basis to produce the Sputnik V vaccine in Argentina in Argentina.Our company will do everything possible to ensure that the vaccine is available as soon as possible for Argentina and for the entire region of Latin America ”.

KEEP READING: